Key clinical point: Adding ilixadencel to sunitinib therapy improved outcomes versus sunitinib monotherapy in patients with newly diagnosed synchronous metastatic renal cell carcinoma.
Major finding: The confirmed overall response rate was 42% with ilixadencel plus sunitinib and 24% with sunitinib monotherapy.
Study details: A randomized, phase 2 study of 70 evaluable patients.
Disclosures: This study was funded by Immunicum. Dr. Lindskog disclosed relationships with Pfizer, Bristol-Myers Squibb, and Ipsen.
Lindskog M et al. ASCO-SITC 2020, Abstract 11.